#USA #Palo Alto #DELFI Diagnostics #Charles Newton #FirstLook Lung

DELFI Diagnostics Welcomes Charles Newton to Its Board of Directors

DELFI Diagnostics, Inc., a pioneering company in the development of innovative AI-driven blood tests for cancer detection, has made a significant announcement regarding its Board of Directors. The organization has appointed Charles Newton, a seasoned professional with extensive experience in healthcare finance and investment banking, to its board, signaling an exciting phase for the company as it prepares for a pivotal moment in its product development journey.

A Veteran in Healthcare Finance

Charles "Charlie" Newton brings nearly three decades of diverse experience in healthcare financial management and executive leadership roles to DELFI. As the company progresses toward a crucial data readout and seeks to submit its lead product, FirstLook™ Lung, to the FDA, Newton's wealth of knowledge and expertise positions him as a valuable asset to the board.

"Charlie's deep financial expertise combined with his experience with emerging companies gives him a unique and valuable perspective. We are thrilled he has chosen to join us in our mission to deliver a paradigm-changing screening test for lung cancer," expressed Liz Homans, Chair of the DELFI Diagnostics Board.

Anticipation for Future Developments

The excitement surrounding Newton's appointment stems from DELFI's current position in its development process. With the unmasking of pivotal clinical data on the horizon, the company is on the brink of advancing FirstLook Lung toward FDA submission. CEO Susan Tousi welcomed Newton, commending his insights that are crucial as they explore transformative partnerships intended to drive DELFI's growth and impact in the clinical arena.

"We are on the cusp of significant advancements, and Charlie's experience is pivotal as we consider strategic partnerships that will boost our clinical impact," stated Tousi.

Addressing a Critical Need in Oncology

Newton's remarks underline the urgency and potential that DELFI aims to address within oncology. "DELFI is tackling one of the most important unmet needs in oncology, and the combination of a differentiated fragmentomics platform, an integrated AI approach, a clear path to FDA approval, and broad reimbursement makes this an exciting time to join the Board," he noted.

A Look at Charlie Newton's Career

Before joining DELFI, Newton held the position of Chief Financial Officer at Lyell Immunopharma, where he led one of the largest biotech IPOs in NASDAQ history. His extensive background in healthcare investment banking includes senior roles at notable firms such as Bank of America Merrill Lynch and Morgan Stanley, during which he successfully advised on approximately $200 billion in mergers and acquisitions.

Newton's current board affiliations include Novavax, Inc., Coherus Oncology, Inc., and Keros Therapeutics, Inc., reflecting his ongoing influence within the healthcare sector.

About DELFI Diagnostics

DELFI Diagnostics stands at the forefront of cancer screening innovation. The company is notable for its FirstLook Lung test, which allows for non-invasive lung cancer screening through a simple blood draw. The test, integrated with regular blood work, is designed for individuals eligible for lung cancer screening, boasting a remarkable negative predictive value of 99.8 percent.

The test empowers individuals to seek follow-up care when necessary, improving early detection of the disease and ultimately driving better patient outcomes. Additionally, DELFI offers DELFI-Tumor Fraction (DELFI-TF), a liquid biopsy service aiding in the monitoring of late-stage cancer patients, enhancing the field of precision medicine.

With partnerships aimed at increasing accessibility and convenience, DELFI Diagnostics continues to pioneer methods to detect cancer earlier and more effectively than traditional modalities. The FirstLook Lung test has yet to achieve FDA clearance, emphasizing the importance of Newton’s new role as DELFI navigates the compliance landscape.

For more information about DELFI Diagnostics and its innovative solutions, visit DELFIDiagnostics.com.